Mayo Clinic study: Parkinson’s drug may trigger compulsions

Share this article:

In a paper chronicling Parkinson's patients treated from 2002 to 2004, Mayo Clinic Physicians outlined 11 cases of patients who became compulsive gamblers after being treated with commonly prescribed drugs to calm their tremors.
The current study documents how specific drugs may be linked to the ill effects. Results will published in the September issue of the Archives of Neurology and are posted on the journal's Web site.
One clinic patient, a 52-year-old man taking Boehringer Ingelheim's Mirapex, began to wager compulsively and lost $100,000 in casinos, according to the study. He also reportedly became obsessed with sex, carried on extramarital affairs and became fixated on pornography. One month after stopping the medicine, his wife told physicians his problems were gone. "I have my old husband back," she said.
Previous reports cited by the Mayo Clinic researchers found only isolated gambling problems with some Parkinson's drugs. One such report found such problems among 1.5 percent of 529 patients treated with Mirapex.
Two separate class action lawsuits have been filed against Boehringer Ingelheim and Pfizer, which co-marketed Mirapex until earlier this year, claiming the companies did not adequately warn patients and doctors about the potential for similar problems.
Boehringer Ingelheim refused to comment on the continuing litigation, a Wall Street Journal report said.

Share this article:
You must be a registered member of MMM to post a comment.

Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.